logo

Living With Cancer

Advocacy

Current Expanded Access Programs

There is no central listing of expanded access or compassionate use programs. If you find a program that’s not listed here, please let us know.

In general, the best way to access a treatment prior to FDA approval is through a clinical trial. All treatments listed here are also being evaluated in clinical trials.

Drug Name (generic) Indication Manufacturer
5-azacytidine refractory acute myelogenous leukemia National Cancer Institute
301-496-5725
Tarceva®, erlotinib Non-Small Cell Lung Cancer Genentech
888-662-6728
Vincristine Sulfate Liposomes Injection (0.16 mg/L) or VSLI A variety of lymphomas and leukemias Inex Inex
604.419.3200 (Vancouver, Canada) ask to speak with the Medical Affairs department
Virulizin® advanced pancreatic cancer Lorus Therapeutics
416-798-1200 ext. 320

Experimental Drugs in Phase 3 Clinical Trials

Remember:

  • No cancer drug works for every patient who uses it
  • Most cancer drugs have significant side effects
  • We don't know if a new treatment will be better than the existing treatment until comparison trials are complete.

There are some new drugs - for example, Gleevec - which offer a dramatic improvement to standard treatments. Unfortunately, most new drugs don't fall into that category.

Experimental drugs in phase 3 clinical trials are generally the drugs closest to FDA review and possible approval. Companies tend to be most open to considering access outside of trials for drugs at this stage of development.

The following experimental drugs are in phase 3 clinical trials. They are a treatment option for patients who can enroll in the clinical trials. If you are interested in access to the treatment outside of the trial, you can contact the company directly.

Remember, you cannot force companies to allow access. However, your call may get them thinking about either expanded access or single patient use. Contact us for help.

Drug Name Manufacturer Disease
MOTEXAFIN GADOLINIUM, Xcytrin® Pharmacyclics France Bui
1-877-676-0330


medicalaffairs@pcyc.com
Brain mets, Non-Small Cell Lung
BMS-247550, Epothilone Bristol-Myers Sqibb Breast
GW572016 GlaxoSmithKline Breast
RPR109881 Aventis Aventis Call Center  1-800-227-3532 contactus@1800Rxtrial.com Breast
Cci 779, temsirolimus Wyeth Breast, Kidney
PTK787 Novartis Joel Hecht, MD, Principal investigator 1-310-206-4303 Colorectal
SU011248 Pfizer - Sugen GIST, Kidney
Edotecarin Pfizer 1-800-716-2949 Glioblastoma Multiforme
IL13-PE38QQR Neopharm Glioblastoma Multiforme
Intratumoral Transferrin-CRM107, TransMID® KS Biomedix - Xenova Patrick Rossi 1-856-273-6057 Glioblastoma Multiforme
ABT-510 Thrombospondin-1 mimetic Abbot Laboratories Ray Knight 1-847-938-1378 raymond.knight@abbott.com Kidney Lymphoma, Sarcoma
BAY 43-9006, Sorafenib Bayer and Onyx Richard Lee, M.D. 1-203-812-3858 Kidney
WX-G250, Rencarex® Wilex Arie Belldegrun, MD 1-310-794-6584 Kidney
NOLATREXED DIHYDROCHLORIDE, Thymitaq® Eximias Pharmaceutical Corporation Gregory Suplick 1-610-560-0637 gsuplick@eximiaspharm.com Liver
T138067 Sodium Tularik Mohammad Hirmand 1-650-825-7278 Liver
Ranpimase, Onconase® Alfacell Diane Scudiery 1-973-748-8082 Malignant Mesothelioma
BBR2778, pixantrone Cell Therapeutics Incorporated (CTI) Non-Hodgkins Lymphoma
Idiotype-KLH Conjugate Vaccine, Favid® Favrille John Gutheil, MD, Protocol chair 1-858-526-8018 Non-Hodgkins Lymphoma, follicular b-cell
MONOCLONAL ANTIBODY B43.13, Oregovomab, OvaRex® Altarex - Unither Pharmaceuticals Ovarian
TLK286, TELCYTA® Telik Incorporated Ovarian, Non-Small Cell Lung
PN401, Triacetyluridine Wellstat Therapeutics Lenny Smith, MS, Protocol chair 1-240-631-2500 ext. 3238 Pancreatic
APC8015, Provenge® Dendreon Prostate
SATRAPLATIN Spectrum Pharmaceuticals and GPC Biotech, AG Faith E. Nathan, MD 1-609-524-1048 sparc-us@gpc-biotech.com Prostate

New Uses for Old Drugs

Companies may apply to the FDA for approval of their drug in new forms of cancer, based on clinical trial results. This approval means that treatment for the new form of cancer is considered non-experimental and your insurance will cover costs. Drugs with multiple approvals include:

Drug Names Original Approval/Date Additional Approvals/Date
Alimta®, Pemetrexed Mesothelioma /February 2004 Non-Small Cell Lung
(NSCLC) /August 2004
Taxotere®, Docetaxel breast /May 1996 NSCLC/December 1999
Prostate/May 2004
Eloxatin®, Oxaliplatin Colorectal, second line/Aug-02 Colorectal, first line/January 2004
Gleevec®, imatinib mesylate Chronic myelogenous leukemia (CML), refractory/May 2001 GIST / February 2002
CML, first line/December 2002
Taxol®, Paclitaxel breast/December 1992 Ovarian/April 1998
NSCLC/June 1998

What if you want a drug that's not listed?

Our Compassionate Use section has extensive information about compassionate use and ways to approach companies that aren't currently offering their drug on a compassionate use basis. If you learn of an expanded access or compassionate use program that we haven’t identified, please let us know.